Gilpin Wealth Management’s Pacira BioSciences PCRX Stock Holding History

Gilpin Wealth Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$226	Hold	9	–	–	﹤0.01%	1084
2026 Q2	$229	Sell	9 -1	-10%	-$24	﹤0.01%	883
2026 Q1	$226	Buy	10 +8	+400%	+$178	﹤0.01%	833
2025 Q4	$52	Buy	+2	New	+$48	﹤0.01%	947

Other funds holding PCRX

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

MPWT

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

DCM

Davis Capital Management Jacksonville, Florida $167M AUM 17.17% 1-Year Est. Return

Gilpin Wealth Management's PCRX Position: Q3 2026 in Review

Gilpin Wealth Management held its Pacira BioSciences (PCRX) position steady in Q3 2026 at 9 shares worth $226. The position accounts for ﹤0.01% of the portfolio, ranked #1084.

Gilpin Wealth Management first reported a position in PCRX in Q4 2025 and has held it in 4 quarters since. The position peaked at $229 in Q2 2026. 6 funds tracked by Wall St. Rank hold PCRX as of Q3 2026.

Gilpin Wealth Management held 9 shares of Pacira BioSciences worth $226 as of Q3 2026.
Gilpin Wealth Management left its Pacira BioSciences share count unchanged in Q3 2026.
Pacira BioSciences made up ﹤0.01% of Gilpin Wealth Management's portfolio in Q3 2026, its #1084 holding.
Gilpin Wealth Management first reported a position in Pacira BioSciences in Q4 2025 and has held it in 4 quarters since.
Gilpin Wealth Management's Pacira BioSciences position peaked at $229 in Q2 2026.
6 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2026.

Based on Gilpin Wealth Management's 13F filing for Q3 2026, filed 9 Oct 2026.